James Hardie Industries plc — FY2020 Form 20-F
Period note: Although the request metadata says “2019 Q4,” this filing is the audited annual report for the fiscal year ended 31 March 2020. The supplied text does not provide a clear standalone fourth-quarter income statement.
Business context and reporting period
James Hardie manufactures fiber cement building products and, following its 2018 Fermacell acquisition, fiber gypsum and cement-bonded boards. Its main markets are North America, Asia Pacific and Europe. Financial statements are prepared under US GAAP and reported in US dollars.
Key financial metrics
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Net sales | US$2,606.8 million | US$2,506.6 million | +4% |
| Gross profit / margin | US$933.7 million / 35.8% | US$831.0 million / 33.2% | +12%; margin +2.6 percentage points |
| Operating income | US$342.5 million | US$351.6 million | -3% |
| Net income | US$241.5 million | US$228.8 million | +6% |
| Diluted earnings per share | US$0.54 | US$0.52 | Higher |
| Cash from operating activities | US$451.2 million | US$304.0 million | +US$147.2 million |
| Capital expenditures | US$193.8 million | US$317.5 million | Lower |
| Cash and cash equivalents | US$144.4 million | US$78.7 million | Higher |
| Long-term debt, net | US$1,354.6 million | US$1,380.3 million | Lower |
| Net debt, as defined by management | US$1,210.2 million | US$1,301.6 million | Lower |
Operating income includes substantial charges: US$84.4 million in asset impairments and US$58.2 million in asbestos adjustments in FY2020. The effective tax rate was 16.1%, versus 23.9% in FY2019. The cash flow increase reflected higher earnings adjusted for non-cash items and increased accounts payable; receivables also rose, including an US$84.7 million US tax receivable.
- North America Fiber Cement: Sales rose 8% to US$1,816.4 million; volume increased 8%. Segment operating income was US$429.3 million, up 12% despite impairment charges.
- Asia Pacific Fiber Cement: Sales fell 6% to US$418.4 million in US dollars, partly reflecting a 6% adverse currency movement. Segment operating income declined 41% to US$58.5 million, including US$36.3 million of impairments.
- Europe Building Products: Sales increased 1% to US$371.4 million. Segment operating income was US$11.2 million, compared with US$10.0 million; excluding acquisition-related costs and impairments, operating income fell 22% to US$30.4 million.
Material changes and unusual items
- North American margin improvement was supported by stronger volume and pricing, better plant performance, and lower input and start-up costs.
- FY2020 impairments included charges related to the planned closure of the Summerville, South Carolina plant, the move to an import-supply model in New Zealand, exit from James Hardie Systems, and other non-core assets.
- The company recorded a US$128.0 million unfavorable actuarial change in the asbestos estimate, partly offset by favorable foreign-exchange effects. Claims received were 16% above actuarial expectations.
- Operating cash used in investing fell substantially from FY2019, principally because the prior year included US$558.7 million for Fermacell and higher capital expenditure.
- The company revised FY2019 and FY2018 cash flow line items for an immaterial error in unpaid property, plant and equipment purchases. It stated the correction did not materially affect the previously reported cash flow statements or financial trends.
Outlook, liquidity, risks and contingencies
- COVID-19 had not materially affected FY2020 fourth-quarter results, but management reported significant uncertainty and adverse effects on construction markets after year-end. Production was reduced to align supply with demand; the company could not provide FY2021 outlook or trend information.
- To strengthen liquidity, the Board suspended dividends until further notice. FY2021 capital expenditure was targeted at US$80–95 million, versus a historic three-year annual average of about US$240 million. AICF contributions were to be paid quarterly rather than as a single July payment.
- At 31 March 2020, the US$500 million revolving credit facility had US$130 million drawn and US$365.4 million available after letters of credit and guarantees. The company reported compliance with debt covenants. Scheduled notes mature in 2025, 2026 and 2028.
- The gross asbestos liability was US$986.4 million; the net unfunded AFFA liability, net of tax, was US$544.4 million. The actuarial estimate is highly assumption-sensitive and includes claims projected through 2072. Management expected FY2021 AICF contributions of approximately US$153.3 million.
- Other material exposures include New Zealand weathertightness litigation, product warranties (US$42.4 million accrued), tax reviews, competition, foreign-exchange and interest-rate movements, raw-material costs, construction-market demand, and environmental and silica-related regulation.
- Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting. The filing identifies asbestos liability valuation and long-lived asset impairment as critical audit matters.
Most important facts for investors to verify
- How COVID-19 affected subsequent demand, production, cash generation and liquidity, given the absence of formal FY2021 guidance.
- The assumptions behind the asbestos actuarial estimate, claim trends, future AFFA payments and potential sensitivity to claims incidence and currency.
- Whether segment performance—particularly North American growth and Asia Pacific weakness—continued after year-end, and the realized benefits and costs of the plant closures.
- Execution of the reduced capital-spending plan, available revolver capacity, debt maturities and compliance with financing covenants.
- The timing and conditions for any resumption of dividends, which were suspended until further notice.